相关实验视频
Updated: Jan 7, 2026
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
10.8K
DPPs-4 抑制剂和牛类皮虫之间的关联:使用 EudraVigilance 数据库报告几率比率分析
Alex Carbonell Pedrero1, Ana Aldea-Perona1,2
1Faculty of Medicine and Life Sciences, Pompeu Fabra University, 08003 Barcelona, Spain.
Pharmaceuticals (Basel, Switzerland)
|December 31, 2025
概括
这项研究发现,双二酶4 (DPP-4) 抑制剂与严重的皮肤疾病 - - 牛皮皮虫 (BP) 之间存在强烈的关联. 增加的风险因素包括男性性别,年龄较大和2型糖尿病,强调需要保持警.
科学领域:
- 药物监督 药物监督 药物监督
- 皮肤病学 皮肤病学
- 内分泌学 在内分泌学.
背景情况:
- 球状皮炎 (BP) 是一种自身免疫性水泡性皮肤疾病.
- 之前的研究表明,双基酶4 (DPP-4) 抑制剂与血压之间存在联系,但这些发现存在争议.
- 与这种联系相关的风险因素需要进一步调查.
研究的目的:
- 使用EudraVigilance数据统计评估DPP-4抑制剂和BP之间的关联.
- 为了确定暴露于DPP-4抑制剂并患有BP的患者的风险因素.
- 将发现与来自FDA不良事件报告系统 (FAERS) 的数据进行比较.
主要方法:
- 一个回顾性,病例/对照观察性研究设计.
- 使用欧洲EudraVigilance数据库 (2007-2024年) 拥有超过1100万份报告.
- 分析了使用报告赔率比率 (ROR) 和费舍尔精确测试的关联.
主要成果:
- 在DPP-4抑制剂使用和血压发展之间发现了显著的关联 (ROR=153.5).
- 确定了关键的风险因素:男性性别 (58.6%),65-85岁 (43.3%),2型糖尿病 (30.4%) 和vildagliptin使用 (44.2%).
- 结果与之前的FAERS数据库分析一致.
结论:
- 有证据支持消费平素 (DPP-4抑制剂) 和血压发展之间的关联.
- 暴露组中的不成比例度更高.
- 高血压可能在暴露数月后出现,需要皮肤病学监测.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
547
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
547
01:19Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K